Hegardt B, Arner B
Eur J Respir Dis. 1981 Oct;62(5):352-9.
In a double-blind crossover study, the wheal inhibiting effect of a new beta-agonist, KWD 2131, and terbutaline was evaluated. The substances were given intracutaneously in five different concentrations, each together with specific allergen or with histamine. During the 2 days' study, 10 patients with known type I-allergy in the skin were randomly assigned to the KWD 2131 or terbutaline group. Both substances gave a dose-dependent inhibition of the allergen-induced wheals. They were, in this respect, equipotent. The greatest protective effect was obtained with the highest doses of both substances (250 micrograms KWD 2131; 25 micrograms terbutaline). In these doses, the inhibition with KWD 2131 and terbutaline was 55 and 45%, respectively (P less than 0.001). Significant inhibition was also seen with the two following lower doses of both substances i.e. 100 and 25 micrograms KWD 2131 and 10 and 2.5 micrograms terbutaline (P less than 0.001-0.01). KWD 2131 and terbutaline did not show any dose-dependent inhibition of histamine-induced wheals. Statistically significant protection against histamine was only reached with the highest dose KWD 2131 (250 micrograms) (P less than 0.05). We conclude that the inhibitory effect of KWD 2131 and of terbutaline on allergen-induced wheal formation in the dose-range tested, is of a selected anti-allergic quality.
在一项双盲交叉研究中，评估了一种新型β-激动剂KWD 2131和特布他林的风团抑制作用。将这些物质以五种不同浓度皮内注射，每种浓度都与特定变应原或组胺一起注射。在为期2天的研究中，10名已知皮肤I型过敏的患者被随机分配到KWD 2131组或特布他林组。两种物质都对变应原诱导的风团产生剂量依赖性抑制作用。在这方面，它们的效力相当。两种物质的最高剂量（250微克KWD 2131；25微克特布他林）产生了最大的保护作用。在这些剂量下，KWD 2131和特布他林的抑制率分别为55%和45%（P<0.001）。两种物质的接下来的两个较低剂量，即100微克和25微克KWD 2131以及10微克和2.5微克特布他林，也观察到了显著抑制作用（P<0.001-0.01）。KWD 2131和特布他林对组胺诱导的风团未显示出任何剂量依赖性抑制作用。仅在KWD 2131的最高剂量（250微克）时才达到对组胺的统计学显著保护作用（P<0.05）。我们得出结论，在测试的剂量范围内，KWD 2131和特布他林对变应原诱导的风团形成的抑制作用具有选择性抗过敏性质。
